Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Client Work

DRAXIS Health completes sale to Jubilant Organosys for US$255 million

Fasken
Reading Time 1 minute read Subscribe
Client

DRAXIS Health

On May 28, 2008, Montreal-based pharmaceutical firm DRAXIS Health Inc. ("DRAXIS") (TSX: DAX) (NASDAQ: DRAX) announced the completion of a statutory arrangement pursuant to which all of the common shares of DRAXIS were acquired by an indirect wholly-owned subsidiary of India-based Jubilant Organosys Ltd. for US$6.00 per common share for a total value of approximately US$255 million. Jonathan Levin and Daniel Batista of Fasken Martineau advised the Special Committee of DRAXIS in connection with the transaction.

    Subscribe

    Receive email updates from our team

    Subscribe